Active — Not RecruitingPhase 3

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

United States617 participantsStarted 2024-01-30

Plain-language summary

The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Completion of the study treatment period of the originating parent study (INCB 54707-301 or INCB 54707-302). * Agreement to use contraception. * Willing and able to comply with the study protocol and procedures. * Further inclusion criteria apply. Exclusion Criteria: * Participation in the extension study could expose the participant to an undue safety risk. * Women who are pregnant (or who are considering pregnancy) or breastfeeding. * Further exclusion criteria apply.

What they're measuring

Proportion of participants with Treatment-Emergent Adverse Events (TEAEs)

Timeframe: up to approximately 56 weeks

Trial details

NCT IDNCT06212999

SponsorIncyte Corporation

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-12-26

View on ClinicalTrials.gov More Hidradenitis Suppurativa (HS) trials